

Anti-Fungal Properties of Actinobacters

Mojgan Mohamad Talebi¹, Shahab Meskini Mood², Hedieh Shamsnia³ and Naser-Aldin Lashgari^{3*}

¹School of Microbiology, ISLAMIC azad university pharmaceutical sciences branch, Iran

²Department of Pharmacology & Toxicology, School of Pharmacy, Tehran University of Medical Sciences, Iran

³Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Iran

*Corresponding author: Naser-Aldin Lashgari, Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran, Iran



ARTICLE INFO

Received: 📅 July 12, 2022

Published: 📅 August 01, 2022

Citation: Mojgan Mohamad Talebi, Shahab Meskini Mood, Hedieh Shamsnia³ and Naser-Aldin Lashgari. Anti-Fungal Properties of Actinobacters. Biomed J Sci & Tech Res 45(3)-2022. BJSTR. MS.ID.007205.

ABSTRACT

Increasing use of antifungal agents and long-term therapeutic approaches has led to an increase in the prevalence of fungal species and their resistance to various drugs. The use of biological agents was proposed as a new and less complication way to control diseases. Streptomycetes actinobacteria are considered to be the most potent producers of bioactive compounds such as enzymes, pesticides, herbicides as well as antibiotics in the world. Actinomycete antifungal activity against fungi such as *Alternaria mali*, *C. gloeosporioides*, *Fusarium oxysporum* f.sp. *cucumerinum* and *Rhizoctonia solani* are shown. In this study, we aim to represent actinobacteria as a novel therapeutic approach for fungal diseases. Data were collected from in vitro and in vivo clinical studies published in English between 2001 and February 2022 and obtained from the PubMed, Google Scholar, Scopus and Cochrane libraries. Data were collected from clinical, in vitro and in vivo studies published between 2001 and February 2022 in English and were obtained from the PubMed, Google Scholar, Scopus and Cochrane libraries.

Keywords: Actinobacteria; Streptomycetes; Fungi; Anti-Fungal Agents; Bioactive Compounds

Introduction

The incidence of fungal infections in humans has increased significantly in the last 30 years. Today, less attention is paid to antifungal drugs, while fungal diseases have a significant share among infectious diseases [1,2]. compared to Antibacterial agents The number of antifungal compounds approved for use in humans is very limited. Also, the high complication of these drugs and their toxicity testify to the discovery of newer and less complication drugs and treatments [3,4]. The increasing use of antifungal agents in long-term treatment strategies has increased the prevalence of resistant fungal species. Secondary microbial metabolites are the main source of compounds with remarkable chemical structures and strong biological activity [5]. Bacteria belonging to the actinomycete group show several physiological and metabolic

properties, such as the production of extracellular enzymes and a variety of secondary metabolites. Their seemingly unlimited ability to produce bioactive compounds makes actinomycetes particularly useful in the development of new drugs [6]. These microorganisms are responsible for producing more than half of the commercially available bioactive compounds, including antibiotics, antifungal and immunosuppressive drugs, antitumor agents, and enzymes. Due to the importance of discovering active compounds with less side effects and stronger against fungi, the aim of this study was to introduce actinomycetes strains with the potential to produce biologically active compounds against fungi and their importance [7,8].

Method of Search

Data were extracted and collected from the PubMed, Google Scholar, Scopus, and Cochrane libraries from the overall term clinical and animal studies published in English between 2001 and February 2022. Search terms included “Fungi” OR “Anti-Fungal” AND “Actinobacteria” OR “Streptomyces” AND “Bioactive compounds”.

Actinobacters

Natural products play a dominant role in the development of new therapeutic agents. Due to their lower side effects than chemical drugs and their greater specificity, actinobacteria represent the most prominent group of microorganisms that produce bioactive compounds that are important in the treatment of many diseases. Most of these molecules are derived from *Streptomyces* [9]. About 58% of bioproducts are derived from the marine sponge-associated actinobacteria, while the remaining are from the actinobacteria associated with mollusks, mangroves, corals, ascidians, and seaweeds. Moreover, extreme habitats such as caves, deserts or Antarctic ecosystems are recognized as valuable sources of actinomycetes producing novel metabolites of pharmacological importance [8]. Natural product production from the actinobacteria like *Actinomadura*, *Salinispora*, *Microbacterium*, *Micrococcus*, *Saccharothrix*, *Saccharopolyspora*, and *Verrucosipora* have antibacterial, antifungal, antiparasitic, antimalarial, immunomodulatory, anti-inflammatory, antioxidant, anti-Alzheimer, analgesic, antiarthritic, antifouling, and anticancer activities [10,11].

Actinobacteria Classification

The current arrangement of Actinobacteria is owing to 16S rRNA sequences. In the actinobacteria classification, the subclass and suborders are eliminated and clades used in these terms earlier are elevated to class and order ranks [12]. The phylum of actinobacteria consists of six classes inclusive of Rubrobacteria, Acidimicrobiia, Coriobacteriia, Thermoleophilia, Nitrospirae, and Actinobacteria. Actinobacteria comprises 43 families while only 10 families belong to the 5 other classes [13]. Two large clades are found in rRNA gene trees associated with class actinobacteria. The first clade comprises of following orders: Micromonosporales, Actinopolysporales, Jiangellales, Glycomycetales, Corynebacteriales, Propionibacteriales, and Pseudonocardiales while the second clade consists of the orders named: Kineosporiales, Bifidobacteriales, Actinomycetales, and Micrococcales [14].

Class Actinobacteria

Actinomycetales: Order Actinomycetales is associated with the family Actinomycetaceae [15] and this family includes genera *Actinomyces*, *Actinobaculum*, *Arcanobacterium*, *Mobiluncus*, and *Varibaculum* [16]. The related species to the first genus,

actinomyces, are *Actinomyces bovis* and *Actinomyces bowdenii*, *catuli*, *dentalis*, *denticolens*, *gerencseriae*, *graevenitzii*, *ruminicola*, *slackii*, *howellii*, *israelii*, *johnsonii*, *massiliensis*, *naeslundii*, *oricola*, *oris*, *radicidentis*, *urogenitalis*, and *viscosus* in the first clade [17]. The second clade contains *Actinomyces canis*, *cardiffensis*, *funkei*, *georgiae*, *hyovaginalis*, *meyeri*, *odontolyticus*, *radinae*, *suimastitidis*, *turicensis*, and *vaccimaxillae*. The last clade is inclusive of *Actinomyces marimammalium*, *hongkongensis*, *hordeovulneris*, and *nasicola* [18]. Other genera have monophyletic clades. *Actinobaculum* genera involves species *Actinobaculum suis* and *Actinobaculum massiliense*, *schaalii*, and *urinale* [19]. *Arcanobacterium* genus includes *Arcanobacterium haemolyticum* and *Arcanobacterium abortusis*, *bernardiae*, *bialowiezensis*, *bonasi*, *hippocoleae*, *phocae*, *plurimalium*, and *pyogenes*. Two species *Mobiluncus curtisii* and *Mobiluncus mulieris* are related to *Mobiluncus* genus [20].

Actinopolysporales: Order Actinopolysporales and the correlated monogeneric family Actinopolysporaceae, comprises of *Actinopolyspora mortivallis* and *Actinopolyspora halophila*.

Bifidobacteriales: Order Bifidobacteriales and family Bifidobacteriaceae comprises of genus *Bifidobacterium*, *Gardnerella* and *Aeriscardovia aeriphila*, *Alloiscardovia omnicoles*, *Metascardovia criceti*, *Parascardovia denticolens*, and *Scardovia inopinata*.

Catenulisporales: Next order is Catenulisporales, and associated families are Catenulisporaceae and Actinospicaceae in which Catenulisporaceae includes the type species *Catenulispora acidiphila* and three other related species are *Catenulispora rubra*, *subtropica*, and *yoronensis* and the Actinospicaceae family is inclusive of *Actinospica robiniae* and *Actinospica acidiphila* type species.

Corynebacteriales: Corynebacteriales order includes the families Corynebacteriaceae, Dietziaceae, Mycobacteriaceae, Nocardiaceae, Segniliparaceae, and Tsukamurellaceae proceed this order in the gene tree. Corynebacteriaceae family contains genus *Corynebacterium* which contains a large number of species and the type species *Turicella otitidis*. Dietziaceae is a monogeneric family which encompasses type species *Dietziamaris* and the related species. Mycobacteriaceae family is a monogeneric, well-defined in the gene tree. It is known for mycolic acids existence and its carbon atoms and the dihydrogenated menaquinones with nine isoprene units [21]. Family Nocardiaceae is paraphyletic and is associated with seven genera however, in the previous tree, the family only consists of *Nocardia* and *Rhodococcus* genera [22]. Segniliparaceae family is monogeneric and it is represented by type species *Segniliparus rugosus* and *Segniliparus rotundus* [23]. Tsukamurellaceae monogeneric family is inclusive of the type species *Tsukamurella paurometabola* and the related species [24].

Frankiales: This order comprises families including Frankiaceae, Cryptosporangiaceae, Geodermatophilaceae, Acidothermaceae, Nakamurellaceae, and Sporichthyaceae [25-30]. Frankiaceae family is monogeneric and consists of type genus *Frankia* and type species *Frankia alni* [30]. Acidothermaceae family includes type genus *Acidothermus* and type species *Acidothermus cellulolyticus* [29]. Cryptosporangiaceae family is related to genus *Cryptosporangium* and the type species *Cryptosporangium arzum* and three linked species *Cryptosporangium aurantiacum*, *minutisporangium* and *japonicum* [28]. Next family is Geodermatophilaceae and the monospecific genus is *Geodermatophilus* and the type species *Geodermatophilus obscurus* [25]. Other genera and species are type species *Blastococcus aggregatus* *Saxobidens* and *jejuensis* and the type species *Modestobacter multiseptatus* and *versicolor*. Family Nakamurellaceae includes three monospecific genera *Humicoccus*, *Nakamurella*, *Saxeibacter* [27]. Sporichthyaceae monogeneric family comprises of two species *Sporichthya polymorpha* and *Sporichthya brevicatena* [26].

Glycomycetales: Only family related to this order is Glycomycetaceae which has three genera. Genus *Glycomyces* type species is *Glycomyces harbinensis* and it has nine other related species [31]. Next, genus *Haloglycomyces*, its type species is *Haloglycomyces albus* [32] and lastly *Stackebrandtia* contains the type species *Stackebrandtia nassauensis* and *Stackebrandtia albiflava* [31].

Jiangellales: The family Jiangellaceae and two genera are correlated with the order. Genus *Jiangella* and its type species *Jiangella gansuensis* and *Jiangella alba* and *alkaliphila*, *Haloactinopolyspora* genus and *Haloactinopolyspora alba* type species are arranged in this order [33].

Kineosporiales: The family Kineosporiaceae and the three genera inclusive of Kineosporia (type species *Kineosporia aurantiaca* and six related species), *Kineococcus* (type species *Kineococcus aurantiacus* and four related species) and *Quadrisphaera* (type species *Quadrisphaera granulorum*) are in this order [34].

Micrococcales: This order encompasses following families: Family Micrococcaceae, Beutenbergiaceae, Bogoriellaceae, Brevibacteriaceae, Cellulomonadaceae, Dermabacteraceae, Dermacoccaceae, Dermatophilaceae, Intrasporangiaceae, Jonesiaceae, Microbacteriaceae, Promicromonosporaceae, Rarobacteraceae, Ruaniaceae, Sanguibacteraceae [35-41].

Micromonosporales: It is related to a single Micromonosporaceae family. The genera composed from this family are *Actinocatenispora*, *Actinoplanes*, *Asanoa* *Micromonospora*, *Krasilnikovia*, *Catelliglobospora* and *Hamadaea*; *Catellatospora*, and *Planosporangium*; *Couchioplanes*, and *Pseudosporangium*; and *Dactylosporangium* and *Virgisporangium* [42,43].

Propionibacteriales: The linked families to this order are Propionibacteriaceae and Nocardioidaceae. Family Propionibacteriaceae contains thirteen genera. This thirteen genera are classified into five clades [44]. Family Nocardioidaceae consists of the genera *Actinopolymorpha*, *Kribbella*, *Nocardioides*, *Aeromicrobium*, and *Marmoricola* [15,45].

Pseudonocardiales: The family Pseudonocardiaceae is grouped in two two clades. The first clade comprises the genera *Kibdelosporangium*, *Pseudonocardia*, *Amycolatopsis*, *Actinomycetospora*, *Saccharomonospora*, *Prauserella*, *Saccharopolyspora*, *Sciscionella*, and *Thermocrispum*. The second clade includes *Lentzea*, *Actinosynnema*, *Saccharothrix*, *Lechevalieria*, and *Umezawaea*. Arabinose and galactose exist in the first clade while mannose, galactose, and sometimes either rhamnose or ribose are found in the second clade [46].

Streptomycetales: Streptomycetaceae family is denoted to genera *Kitasatospora*, *Streptomyces* and *Streptoverticillium* [45].

Streptosporangiales: The families Streptosporangiaceae, Nocardiopsaceae, Thermomonosporaceae are assigned for this order. Family Streptosporangiaceae is related to 11 genera. Family Nocardiopsaceae and family Thermomonosporaceae are similarly composed of 5 genera [47].

Class Acidimicrobiia

Order Acidimicrobiales: It involves two main families Acidimicrobiaceae and Iamiaceae. The family Acidimicrobiaceae consists of four monospecific genera including *Acidimicrobium*, *Ferrimicrobium*, *Ferrithrix*, and *Ilumatobacter*; The family Iamiaceae encompasses the monospecific genus *Iamia* [40].

Class Coriobacteriia

Coriobacteriales: This order contains the single Coriobacteriaceae family. The family encompasses six clades. One clade includes the monospecific genus *Coriobacterium* and *Collinsella aerofaciens*, *intestinalis*, and *stercoris*. *Denitrobacterium detoxificans*, *Atopobium minutum*, *Adlercreutzia equolifaciens*, *Asaccharobacter celatus*, and *Enterorhabdus mucosicola*, *faecicanis*, *Cryptobacterium curtum*, *fossor*, *parvulum*, *Gordonibacter pamelaeeae*, *rimae*, and *vaginae*, and *Olsenella uli* and *profusa*, *Eggerthella lenta* and *sinensis*, and *Paraeggerthella hongkongensis*; and *Slackia exigua*, *heliotrinireducens*, and *isoflavoniconvertens* [48].

Nitriliruptoria: The order Nitriliruptorales and the family Nitriliruptoraceae are assigned for this class [49].

Class Rubrobacteria

4.6.1. Rubrobacterales: This order is mainly represented by the family Rubrobacteraceae and the genus *Rubrobacter* [50].

Mechanisms of Actinobacteria Action

Actinobacteria are a group which are significant as producers of wide range of antibiotic products. Novobiocin, also termed as cathomycin or albamycin is produced by *Streptomyces niveus*. This compound is an aminocoumarin antibiotic. It targets GyrB subunit of bacterial DNA gyrase which play a role in energy transduction [51]. Abyssomicin C is produced by marine *Verrucospora* strain and strongly inhibits para-aminobenzoic acid. It acts potently against gram positive bacteria [52]. Bacteriocins are ribosomally manufactured and usually small peptides (<10 kDa) produced by bacteria in order to impede the growth of related bacteria species. These antimicrobial agents can also have a broad spectrum activity against non-related species [53]. Some can also reveal anti-allergic, antitumor, anti-inflammatory, antinociceptive activities and regulate blood pressure. Lanthipeptides are ribosomally synthesized peptides which undergo posttranslational alteration that induce rare amino acids production and display various bioactivities including antifungal, antimicrobial, and antiviral activities. Their modifications occur proceeding two main reactions: dehydration of threonine or serine residues on the way to form Dha or Dhb, and cyclization to form Lan or MeLan [54]. Lantibiotics are the term used for lantheptides exhibiting antimicrobial activity in which the cell wall synthesis is hindered by binding to lipid II, hence the merge of precursors with the cell wall and thus the cell membrane functions will be aberrant [55,56].

Lantibiotics are divided into three subclasses based on their biosynthetic machinery [55]. Type one are modified by cyclase LanC and the dehydratase LanB, Type two are modified by bifunctional enzyme, LanM, with both activities and type three are modified by the type III is modified by a trifunctional enzyme, LanKC with kinase, lyse and cyclase activities. Microbisporicin A1 and A2 are classified in type one and produced by *Microbispora corallina* and processed by LanB and LanC [57]. Variacin is type two, processed by a bifunctional LanM and produced by *Kocuria varians* [58]. Labyrinthopeptins A1, A2 and A3 are type three, processed by LanKC and *Actinomadura namibiensis* [59]. Microbisporicin or

NAI-107, a type one lantibiotic, was chiefly observed in strains of *Actinoallomurus* spp [60]. And *Microbispora corallina* [61]. There are two main congeners discovered named as microbisporicin A1 and A2. Both of them function as cell wall synthesis inhibitors and develop bacteriocidal effect. They bind to lipid II and also to other bactoprenol-bound precursors and accordingly impairing cell membrane [62]. Microbisporicin/NAI-107 is a potent lantibiotic against both aerobic and anaerobic Gram-positive pathogens.

Planosporicin or lantibiotic 97518, type one lantibiotic, is produced by *Planomonospora* sp. DSM 14920 and is a cell wall synthesis inhibitor likewise. Planosporicin and microbisporicin/NAI-117 share mostly the same structure and mechanism of action [63]. Variacin is a type two lantibiotic, and was identified in two strains of *Kocuria varians*. Growth of an extensive range of Gram-positive food spoilage bacteria are hindered by variacin [58]. Michiganin A is known to be manufactured by *Clavibacter michiganensis* subsp. *michiganensis* [64]. Holtmark and al. suggested that the function of this compound is by inhibiting cell wall synthesis similar to the previous discussed compounds. It has a narrow spectrum of targets [65]. Actagardine is another type two lantibiotic which blocks the transglycosylation reaction and consequently inhibits the cell wall synthesis [66]. It shows a potent bioactivity against Gram-positive pathogens, specially *Clostridium* spp. And *Streptococcus* spp [67]. Lantibiotics belonging to the cinnamycin group are categorized as type two and known as Cinnamycin, duramycin and ancovenin. Cinnamycin is exclusively produced by *Streptomyces* spp while Duramycin is produced from *Streptomyces cinnamoneus* [68]. Cinnamycin inhibits anaerobic bacteria, *Bacillus subtilis*, yeasts and fungi and also impedes the proliferation of herpes simplex virus 1 [69]. Labyrinthopeptins, including LabA1, LabA2 and LabA3, are type 3 lantibiotic and were observed in *Actinomadura namibiensis* DSM 6313 [70]. LabA1 exhibits antiviral activity against HIV and HSV, in which the cell entry of these viruses is impeded and cell-to-cell viral transmission of HIV is prevented [71]. NAI-112 is another type 3 lantibiotic is produced by *Actinoplanes* sp. DSM 24059 and act moderately against *Staphylococcus* spp. and *Streptococcus* spp with the mechanism explained above [72].

Pharmacological Properties of Actinobacters

Table 1: Anti-Microbial properties of Actinobacteria.

Actinobacter	Active Component	Bioactivity	Reference
<i>A. baumannii</i>	A mixture of iturin A2, iturin A3, and iturin A6 (Antifungal)	Inhibits the growth of <i>Cryphonectria parasitica</i> , <i>Glomerella glycines</i> , <i>Phytophthora capsici</i> , <i>Fusarium graminearum</i> , <i>Botrytis cinerea</i> , and <i>Rhizoctonia solani</i>	Hemala L, et al. [131]

Nocardiopsis prasina, Streptomyces violarius, Streptomyces krainiskii, and Streptomyces tsusimaensis	-	Antimicrobial activity against Bacillus subtilis, methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli ATCC 25922, Acinetobacter baumannii, Salmonella Typhi, and Candida albicans	Holtsmark I, et al. [64]
HAAG3-15 the most closely to Strep- tomyces sporoclivatus and S. antimy- coticus	Azalomycin B	Showed antagonism against Fusarium oxysporum f. sp. cucumerinum, Cory- nespora cassicola, Setosphaeriaturcica turcicaf, Colletotrichum orbiculare, Alternaria solani, Helminthosporium maydis, Sphacelotheca reiliana, Sclero- tinia sclerotiorum, Phytophthora sojae, and Rhizoctonia solani	Holtsmark I, et al. [65]
Streptomyces capitiformicae 1H-SSA4, Streptomyces amphotericinicus 1H-SSA8 and Streptomyces lasiicapitis 3H-HV17, Streptomyces sp. 1H-GS5, and Streptomyces sp. 1H-XA2	A novel polyene amide compound and furamycins I and II	Rhizoctonia solani, Fusarium oxyspo- rum, Curvularia lunata, Corynespora cassii- cola, Setosphaeriaturcica turcicaf, Colletotrichum orbiculare, Alternaria solani, Helminthosporium maydis, Sphacelo- theca reiliana, Sclerotinia sclerotiorum, Phytophthora sojae, Phytophthora capsici, and Phytophthora infestans	Hoyle L, et al. [20]
Streptomyces sporoclivatus, Strepto- myces cavourensis, Streptomyces capitiformicae, and Streptomyces pratensis	azalomycins F4a, azalomycins F5a, bafilomycin B1, actinolactomycin, dimeric dinactin, tetranactin, dynactin, maremycin G, and a new maremycin analogue	Sclerotinia sclerotiorum	Hug JJ, et al. [74]
WA23-4-4 isolated from the intestinal tract of Periplaneta americana considered as a novel Streptomyces	3-Acetyl benzoyl amide	Showed significant antifungal activity against Candida albicans ATCC 10231, Aspergillus niger ATCC 16404, Tricho- phyton rubrum ATCC 60836, and Aspergillus fumigatus ATCC 96918	Hui MLY, et al. [124]

Micromonospora auratinigra, a member of the family Micromonosporaceae, and Kocuria kristinae	Chloroanthraquinone, a novel bafilomycin analogue, and novel antimicrobial peptide	Showed inhibitory activity against <i>Bacillus subtilis</i> , <i>Candida albicans</i> , and <i>Escherichia coli</i> (Only the peptide from <i>Kocuria kristinae</i>)	Inderiati S [117]
<i>Streptomyces</i> , <i>Nocardia</i> , and <i>Streptosporangium</i> which ambiguously matched with <i>Streptomyces niveus</i> NRRL 2466 (T) and <i>Streptomyces pulveraceus</i> NBRC 3855 (T)	2,5-bis(1,1-dimethylethyl) phenol and benzenoacetic acid	Showed inhibitory activity against <i>Staphylococcus aureus</i> MTCC 96, <i>Escherichia coli</i> MTCC 40, <i>Candida albicans</i> MTCC 227, <i>Staphylococcus aureus</i> (MRSA) ATCC 43300, <i>Staphylococcus saprophyticus</i> , and <i>Bacillus pumillus</i>	Iorio M, et al. [61]
Most closely related to <i>Pilimelia columellifera</i> subsp. <i>pallida</i> GU269552(T)	Silver nanoparticles capped with proteins	Showed inhibitory activity against <i>Malassezia furfur</i> , <i>Trichophyton rubrum</i> , <i>Candida albicans</i> , and <i>Candida tropicalis</i>	Janardhan A, et al. [91]
VITGAP240 and VITGAP241 with predominant genus of <i>Streptomyces</i>	Type I polyketide synthases (PKS-I), PKS-II, and non-ribosomal peptide synthases (NRPS)	Showed inhibitory activity against <i>Candida albicans</i>	K Sharma, et al. [119]
<i>Streptomyces</i> sp. TD025 mostly closest to <i>Streptomyces cirratus</i>	Antimycin urauchimycins A and B	Showed inhibitory activity against <i>Candida albicans</i>	Kämpfer P, et al. [28]
<i>Streptomyces albidoflavus</i> NBRC13010 (AS25)	Non-polyenic lactone, antimycin A19	Showed inhibitory activity against resistant <i>Candida tropicalis</i> R2 and <i>Pythium irregular</i> (resistant to polyenes)	Kämpfer P [38]
<i>Pseudomonas frederiksbergensis</i> BZ21, <i>Pseudomonas frederiksbergensis</i> BZ27, <i>Pseudomonas fluorescens</i> BZ64, <i>Serratia proteamaculans</i> BZ56, and <i>Serratia liquefaciens</i> BZ65	Components in extraction were similar to Tetracycline and Rifampine (but further studies are needed) and serraticin A	Showed inhibitory activity against <i>Escherichia coli</i> , <i>Shigella flexneri</i> , <i>Salmonella enterica</i> , <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus aureus</i> , <i>Candida albicans</i> , and <i>Cryptococcus neoformans</i>	Kämpfer P [132]




Figure 1: Actinobacteria properties.

Several studies different properties of Actinobacteria and shown their usage in various disorders. Here in we are going to represent their benefits in different situation as below (Table 1) (Figure 1).

Anti-Bacterial Effects: Bacterial pathogens can lead to deadly infectious diseases. Most bacterial infections are very difficult to treat due to antibiotic resistance obtained by pathogens [73]. Bacterial agents' resistance to a variety of antibiotics is spreading alarmingly around the world. New natural-derived antibiotics have also declined sharply in recent years. Due to the declining effectiveness of the drug on the market, researchers have begun to develop new alternatives for treating infections caused by pathogens. Thus, this has led to the discovery of strains of marine actinobacteria [74]. Hence, marine *Streptomyces* antibiotics have been used to prevent or treat diseases stimulated by microorganisms [75]. Continuous research is underway to develop an effective therapeutic drug by isolating biologically active molecules from rare actinobacterial bacteria [76].

Anti-Cancer Effects: Cancer is one of the most serious and deadly diseases. Current treatments including chemotherapy, immunotherapy, surgery and radiotherapy have not been very effective to date. Many antitumor compounds have been reported to be derived from Marine *Streptomyces* [77]. Marine actinobacteria are rich sources of antitumor compounds, for example, actinomycin,

anthracycline, aureolic, mitomycin, bleomycin, pentostatin, resistomycin [78]. These factors are effective in the prevention and treatment of cancer with apoptosis, mitochondrial permeability, inhibition of signal transduction, morphological changes due to irregular cell differentiation, angiogenesis, DNA encoding and inhibition of RNA polymerase activity [79,80].

Anti-Inflammatory Effects: Inflammation occurs as an immune response to infection, irritation, or tissue damage. Various factors such as blunt trauma, foreign bodies, vibrations and chronic pressure are involved in causing inflammation [81]. Many natural products such as resveratrol, quercetin, curcumin, etc. have been used to revive the inflammatory process in various diseases [82-84]. Secondary bioactive metabolites from *Streptomyces* sp. It has been proven to have anti-inflammatory activity. Therefore, these compounds can be used as an up-to-date treatment method in the treatment of inflammatory diseases [85,86].

Anti-Malaria Effects: Malaria is caused by the protozoan, *Plasmodium*, which is parasitic in nature and accountable for more than 200 million reported clinical cases and over 3 million mortalities annually. *P. falciparum*, the causative agent, is becoming increasingly resistant to most of the drugs [87]. New therapeutic strategies are urgently required to battle this disease. Some of the compounds derived from the marine actinobacteria possess extremely high anti-plasmodial activity [88].

Anti-Viral Effects: Also, the antiviral properties of actinobacteria have been proven to play this role by various methods such as biological control of human anthropogenic virus contamination, control of disease transmission in wastewater and contaminated effects of chemotherapy for viral diseases [89]. These activities are mostly used in coastal areas, where water is needed for recreational activities or in the food industry, and directly affect the lifestyle and economy of the people [90].

Anti-Oxidative Effects: Antioxidants prevent deterioration, damage or destruction by the oxidation process. These bioactive compounds protect the body against oxidative stress by blocking or delaying oxidative damage caused by reactive oxygen species (ROS) [91]. Various mechanisms such as inhibiting the formation of free radicals, eliminating oxygen molecules and chelating metal prooxidants have been considered for them [92].

Human Fungal Diseases: Pathogenesis and Current Treatment: Challenges Facing Invasive fungal infections are a growing threat to human health. In the developed world, these infections are mainly occurring in the increasingly contextual [93]. Invasive immunosuppressive therapies are one of the treatments. Total mortality for invasive diseases caused by *Candida* species [94]. And *Aspergillus* spp. 30-50%. Despite the emergence of new diagnostic and therapeutic strategies in the world, there are 1 million cases of *Cryptococcus* Which leads to the death of 675,000 people [95]. Due to the high degree of phylogenetic relationship between fungi and humans The development of therapeutic methods can be one of the main objectives of the study [96]. Fungi produce a large set of secondary enzymes and metabolites to fight and digest the outside world in order to fight for survival and with each other. Many antimicrobial agents are isolated from the fungi themselves. The best example is penicillin, which was isolated from *Penicillium notatum* (*Penicillium chrysogenum*) [97]. Most of studies concerning four human fungal pathogens that cause invasive infections including *C. albicans*, *C. neoformans*, *A. fumigatus*, and *H.capsulatum*. *C. albicans* is a commensal fungus which exists as a normal microflora in the human body but becomes pathogenic if the host immune defense system is weakened [98,99]. Currently, five classes of antifungal agents are used orally or intravenously to treat fungal infections in humans: polyenes, pyrimidine analogues, allylamines, azoles, and echinocandins [100].

Anti-Fungal Properties of Actinobacters; Novel Insight Against Fungi Pathogenesis: Lamari and al. exploited the new dithiolopyrrolone antibiotics, named as 3-methyl-2-butenoylpyrrothine, tigloylpyrrothine, and n-butyropyrrrothine in addition to known iso-butyropyrrrothine and thiolutine from an actinomycete strain, *Saccharothrix* sp., which was extracted from saharian palm grove soil at Adrar, south Algeria [101]. These products revealed high antibacterial activity against

Gram-positive bacteria *Bacillus coagulans*, *Bacillus subtilis*, and *Micrococcus luteus* except for *Staphylococcus aureus*. these compounds showed no or weak antibacterial activity against gram negative bacteria except *Klebsiella pneumoniae* that was highly inhibited [101]. Merrouche and al. in 2010 succeeded to extract the new dithiolopyrrolone derivatives valerylpyrrothine, isovalerylpyrrothine, formylpyrrothine and the known aureothricin. They showed moderate efficiency against some fungi *Penicillium expansum*, *Mucor ramanniamus*, and *Aspergillus carbonarius* [102]. Further, Merrouche and al. in 2011 performed another study and the new dithiolopyrrolone (PR2, PR8, PR9 and PR10) were purified from the broth of *Saccharothrix algeriensis*. These four antibiotics were named as crotonyl-pyrrothine, sorbyl-pyrrothine, 2-hexonyl-pyrrothine and 2-methyl-3-pentenyl-pyrrothine, respectively. PR8 showed highest activity against gram negative bacteria compared to others. All compounds except PR10 was observed to have a moderate antibacterial activity against the tested fungi and yeasts. Moreover, PR10 demonstrated higher activity against *Candida albicans* and *A. carbonarius*. PR8 showed to be most active against gram positive bacteria [103]. Benzoyl-pyrrothine dithiolopyrrolone was obtained from *Saccharothrix algeriensis* NRRL B-24137, which showed high bioactivity against *Listeria monocytogenes* and acceptable MIC against several Gram-positive bacteria and filamentous fungi [104]. A new anthracycline antibiotic mutactimycin PR was discovered by a study conducted by Zituni and al., isolated from *Saccharothrix* sp. SA 103 strain and they also isolated the known mutactimycin C. These compounds revealed moderate bioactivity against some Gram-positive bacteria and fungi specifically *Bacillus subtilis*, *Saccharomyces cerevisiae*, and *Mucor ramannianus* [105].

Angucyclinone which is mostly isolated from the genus *Streptomyces* and also from *Actinomadura*, *Nocardia* and *Streptosporangium* genera is related to tetracyclines and anthracycline. It has broad spectrum and has a good efficacy against *Micrococcus luteus* ATCC 9314 and *Bacillus subtilis* ATCC 6633 [106]. *Nonomuraea* sp. NM94 strain secretes some antibiotics that some of them are shown to be active towards some Gram-positive bacteria, yeast, and fungi [107]. *Saccharothrix* species were the initial source of chloramphenicol production. Aouiche and al. indicated that *Saccharothrix* sp. PAL54A strain produces the known chloramphenicol [108]. *Streptomyces* sp. WR1L1S8 was utilized and its metabolites were isolated. The metabolites were the new polyketide known as 2-hydroxy- γ -pyrone tautomeric along with phaeochromicins B, C, and E. They showed inhibiting activity against the growth of both the Gram-positive and Gram-negative bacteria. Polyketide compound revealed a bacteriostatic activity against methicillin-resistant *Staphylococcus aureus* [109]. Actinomycete strain SA198 was isolated from a Saharan soil sample of Algeria by Boubetra and al. and Pure metabolites were extracted

which exhibited moderate activities against gram negative and gram positive bacteria and potent effects against phytopathogenic and toxinogenic fungi including *Aspergillus carbonarius*, *Penicillium expansum*, *Mucor ramannianus* [110]. Another study by Adel and al. isolated actinobacteria strain PAL114 from a Saharan soil in Algeria which produces antibacterial compounds. Two of these bioactive compounds are P44 and P40. The P40 is efficiently active against *Candida albicans*, *Bacillus subtilis*, and *Staphylococcus aureus* [111].

Chemically named, 2-amino-N-(2-amino-3-phenylpropanoyl)-N-hydroxy-3-phenylpropanamide, which was purified from *Streptomyces* WAB9, revealed an appreciable antibiotic effect against some drug-resistant bacteria, filamentous fungi and yeasts. The effect was most notably against *Pseudomonas aeruginosa* IPA1 [112]. Isolation of di-(2-ethylhexyl) phthalate from the strain *Streptomyces* sp. G60 was reported by Driche, et al. [113]. This compound showed strong compound against different strains of *Staphylococcus aureus* and MRSA [113]. The actinobacterium strain ABH26 has shown that produces antimicrobial products. Two new cyanogriside antibiotics named cyanogriside I and cyanogriside J along with the three caerulomycins, caerulomycin F caerulomycin A and caerulomycinonitrile are produced by the strain. All the compounds had effect against the gram positive bacteria and caerulomycin F emerged the most bioactivity against gram positive bacteria and also fungi [114]. Extensive research is underway to identify new antifungal compounds from actinobacteria that are effective against pathogenic fungi

(Table 2). Among these bioactive compounds, we can mention scopafungin, candidi plancin, rapamycin, phthalates, etc., which have significant antifungal properties [115]. Metabolites derived from actinobacteria for applications such as cartilage tissue engineering, transport Drugs and nerve regeneration have been used. These antifungal metabolites include nystatin (*Streptomyces noursei*), amphotericin B (*Streptomyces nodosus*), and natamycin. (*Streptomyces natalensis*). *Streptomyces* sp. DA11 was found to be associated with *Craniella* sp. This species produced exoenzyme chitinase which showed significant antifungal activity against *Aspergillus* sp and *Candida* sp [116]. kasugaensis is a bactericidal and fungicidal metabolite secreted by *Streptomyces kasugaensis* and acts as an inhibitor of protein biosynthesis in microorganisms ([117,118]. Isolated polyoxins B and D from the metabolites *Streptomyces cacaoi* var. *asoensis*. These substances interfere with the synthesis of the fungal cell wall by inhibiting the synthesis of chitin [119]. The validamycin family was identified by researchers in the Takeda chemical industry in a greenhouse experiment for the treatment of pod blight in rice plants caused by *Rhizoctonia solani*. Validamycin A, the major and most active component of the complex, was isolated from *Streptomyces hygrosopicus* var. *limoneus* [120]. Inside the fungal cell, validamycin is converted to credoxylamine A, a potent trehalose inhibitor that suppresses the breakdown of intracellular trehalose. Trehalase plays an essential role in glucose transport in insects and fungi. This procedure gives validamycin A a desirable biological choice because vertebrates do not depend on the hydrolysis of trehalose disaccharide for their [121].

Table 2: Anti-Fungal properties of Actinobacteria.

Actinobacter	Active Component	Antifungal Activity	Reference
<i>A. baumannii</i>	A mixture of iturin A2, iturin A3, and iturin A6 (Antifungal)	Inhibits the growth of <i>Cryphonectria parasitica</i> , <i>Glomerella glycines</i> , <i>Phytophthora capsici</i> , <i>Fusarium graminearum</i> , <i>Botrytis cinerea</i> , and <i>Rhizoctonia solani</i>	Hemala L, et al. [131]
<i>Nocardiopsis prasina</i> , <i>Streptomyces violarius</i> , <i>Streptomyces krainskii</i> , and <i>Streptomyces tsusimaensis</i>		Antifungal activity against <i>Candida albicans</i>	Holtmark I, et al. [64]

HAAG3-15 the most closely to <i>Streptomyces sporoclivatus</i> and <i>S. antimycoticus</i>	Azalomycin B	<p>Showed antagonism against <i>Fusarium oxysporum</i> f. sp. <i>cucumerinum</i>, <i>Corynespora cassiicola</i>, <i>Setosphaeria turcica</i>, <i>Colletotrichum orbiculare</i>, <i>Alternaria solani</i>, <i>Helminthosporium maydis</i>, <i>Sphacelotheca reiliana</i>, <i>Sclerotinia sclerotiorum</i>, and <i>Rhizoctonia solani</i></p>	Holtmark I, et al. [65]
<p><i>Streptomyces capitiformicae</i> 1H-SSA4, <i>Streptomyces amphotericinicus</i> 1H-SSA8 and <i>Streptomyces lasiicapitis</i> 3H-HV17, <i>Streptomyces</i> sp. 1H-GS5, and <i>Streptomyces</i> sp. 1H-XA2</p>	A novel polyene amide compound and furamycins I and II	<p>Showed antagonism against <i>Rhizoctonia solani</i>, <i>Fusarium oxysporum</i>, <i>Curvularia lunata</i>, <i>Corynespora cassiicola</i>, <i>Setosphaeria turcica</i>, <i>Colletotrichum orbiculare</i>, <i>Alternaria solani</i>, <i>Helminthosporium maydis</i>, <i>Sphacelotheca reiliana</i>, and <i>Sclerotinia sclerotiorum</i></p>	Hoyle L, et al. [20]
<p><i>Streptomyces sporoclivatus</i>, <i>Streptomyces cavourensis</i>, <i>Streptomyces capitiformicae</i>, and <i>Streptomyces pratensis</i></p>	<p>azalomycins F4a, azalomycins F5a, bafilomycin B1, actinolactomycin, dimeric dinactin, tetranactin, dynactin, maremycin G, and a new maremycin analogue</p>	<i>Sclerotinia sclerotiorum</i>	Hug JJ, et al. [74]
WA23-4-4 isolated from the intestinal tract of <i>Periplaneta americana</i> considered as a novel <i>Streptomyces</i>	3-Acetyl benzoyl amide	<p>Showed significant antifungal activity against <i>Candida albicans</i> ATCC 10231, <i>Aspergillus niger</i> ATCC 16404, <i>Trichophyton rubrum</i> ATCC 60836, and <i>Aspergillus fumigatus</i> ATCC 96918</p>	Hui MLY, et al. [124]
<i>Micromonospora auratinigra</i> , a member of the family <i>Micromonosporaceae</i> , and <i>Kocuria kristinae</i>	Chloroanthraquinone, a novel bafilomycin analogue, and novel antimicrobial peptide	Showed inhibitory activity against <i>Candida albicans</i>	Inderiati S [117]

Streptomyces, Nocardia, and Streptosporangium which ambiguously matched with Streptomyces niveus NRRL 2466 (T) and Streptomyces pulveraceus NBRC 3855 (T)	2,5-bis(1,1-dimethylethyl) phenol and benzeneacetic acid	Showed inhibitory activity against Candida albicans MTCC 227	Hug JJ, et al. [74]
Most closely related to Pilimelia columellifera subsp. pallida GU269552(T)	Silver nanoparticles capped with proteins	Showed inhibitory activity against Malassezia furfur, Trichophyton rubrum, Candida albicans, and Candida tropicalis	Hui MLY, et al. [124]
VITGAP240 and VITGAP241 with predominant genus of Streptomyces	Type I polyketide synthases (PKS-I), PKS-II, and non-ribosomal peptide synthases (NRPS)	Showed inhibitory activity against Candida albicans	Iorio M, et al. [61]
Streptomyces sp. TD025 mostly closest to Streptomyces cirratus	Antimycin urauchimycins A and B	Showed inhibitory activity against Candida albicans	Janardhan A, et al. [91]
Streptomyces albidoflavus NBRC13010 (AS25)	Non-polyenic lactone, antimycin A19	Showed inhibitory activity against resistant Candida tropicalis R2	K Sharma, et al. [119]
Pseudomonas frederiksbergensis BZ21, Pseudomonas frederiksbergensis BZ27, and Pseudomonas fluorescens BZ64	serraticin A	Showed inhibitory activity against Candida albicans and Cryptococcus neoformans	Kämpfer P, et al. [28]

Conclusion

The growing need for drug discovery has led to new technologies in clinical trials. Intensive research is being developed into the discovery and synthesis of less complication and more effective antifungal drugs [122]. Due to the various applications of natural compounds in medicine, food and health in the last six decades, more than ten thousand natural compounds have been derived from various microbial sources. Actinomycetes are most commonly distributed in environments such as terrestrial, marine, or extreme conditions. Streptomyces is the largest genus of Actinobacteria in the family Streptomycetaceae [123]. These are gram-positive bacteria with high GC content that perform various functions such as antibacterial, anti-fouling, anti-fungal, anti-inflammatory, anti-parasitic, anti-tumor, anti-viral, insecticidal, growth-promoting metabolites and enzyme inhibitors [124]. This is one of the important reasons why this group of organisms has been widely considered in the treatment of various diseases [125]. In this study,

actinobacteria are described and introduced as a new antifungal agent that can be widely used in the prevention and treatment of fungal diseases [126-141].

Declarations of Interest

None.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgment

None.

References

1. Das M, Royer TV, Leff LG (2007) Diversity Of Fungi, Bacteria, And Actinomycetes On Leaves Decomposing In A Stream. Applied And Environmental Microbiology 73(3): 756-767.

2. Doumbou CL, Hamby Salove M, Crawford DL, Beaulieu C (2001) Actinomycetes, Promising Tools To Control Plant Diseases And To Promote Plant Growth. *Phytoprotection* 82: 85-102.
3. Bressan W (2003) Biological Control Of Maize Seed Pathogenic Fungi By Use Of Actinomycetes. *Biocontrol* 48: 233-240.
4. Kathiresan K, Balagurunathan R, Selvam MM (2005) Fungicidal Activity Of Marine Actinomycetes Against Phytopathogenic Fungi. *Indian Journal of Biotechnology* 4: 271-276.
5. Costa FG, Zucchi TD, Melo ISD (2013) Biological Control Of Phytopathogenic Fungi By Endophytic Actinomycetes Isolated From Maize (*Zea Mays* L.). *Brazilian Archives Of Biology And Technology* 56(6): 948-955.
6. Bhatti AA, Haq S, Bhat RA (2017) Actinomycetes Benefaction Role In Soil And Plant Health. *Microbial Pathogenesis* 111: 458-467.
7. Zaitlin B, Turkington K, Parkinson D, Clayton G (2004) Effects Of Tillage And Inorganic Fertilizers On Culturable Soil Actinomycete Communities And Inhibition Of Fungi By Specific Actinomycetes. *Applied Soil Ecology* 26: 53-62.
8. Sharma M, Dangi P, Choudhary M (2014) Actinomycetes: Source, Identification, And Their Applications. *Int J Curr Microbiol App Sci* 3(2): 801-832.
9. Luisa BG (2012) Actinomycetes In Biotechnology. In: Luisa BG (Edt.), Elsevier, Netherlands.
10. Genilloud O (2017) Actinomycetes: Still A Source Of Novel Antibiotics. *Natural Product Reports* 34(10): 1203-1232.
11. Solecka J, Zajko J, Postek M, Rajnisz A (2012) Biologically Active Secondary Metabolites From Actinomycetes. *Open Life Sciences* 7(3): 373-390.
12. Ludwig W, Euzéby J, Schumann P, Busse HJ, Trujillo ME, et al. (2012) Road Map Of The Phylum Actinobacteria. *Bergey's Manual® Of Systematic Bacteriology*. Springer.
13. Mohammadipanah F, Dehghani M (2017) Classification And Taxonomy Of Actinobacteria. *Biology And Biotechnology Of Actinobacteria*. Springer.
14. Salam N, Jiao JY, Zhang XT, Li W (2020) Update On The Classification Of Higher Ranks In The Phylum Actinobacteria. *Int J Syst Evol Microbiol* 70(2): 1331-1355.
15. Schaal K, Schofield G, Pulverer G (1980) Taxonomy And Clinical Significance Of Actinomycetaceae And Propionibacteriaceae. *Infection* 8: S122-S130.
16. Schaal KP, Yassin AF, Stackebrandt E (2006) The Family Actinomycetaceae: The Genera *Actinomyces*, *Actinobaculum*, *Arcanobacterium*, *Varibaculum*, And *Mobiluncus*. *The Prokaryotes* 3: 430-537.
17. Siqueira JF, Rôças IN, Souto R, De Uzeda M, Colombo AP (2002) *Actinomyces* Species, *Streptococci*, And *Enterococcus Faecalis* In Primary Root Canal Infections. *J Endod* 28(3): 168-172.
18. Lawson PA, Falsen E, Åkervall E, Vandamme P, Collins MD (1997) Characterization Of Some Actinomyces-Like Isolates From Human Clinical Specimens: Reclassification Of *Actinomyces Suis* (Soltys And Spratling) As *Actinobaculum Suis* Comb. Nov. And Description Of *Actinobaculum Schaalii* Sp. Nov. *Int J Syst Bacteriol* 47: 899-903.
19. Fendukly F, Osterman BR (2005) Isolation Of *Actinobaculum Schaalii* And *Actinobaculum Urinale* From A Patient With Chronic Renal Failure. *J Clin Microbiol* 43(7): 3567-3569.
20. Hoyles L, Collins MD, Falsen E, Nikolaitchouk N, McCartney (2004) Transfer Of Members Of The Genus *Falcivibrio* To The Genus *Mobiluncus*, And Emended Description Of The Genus *Mobiluncus*. *Syst Appl Microbiol* 27(1): 72-83.
21. Bergey DH, John G Holt (1994) *Bergey's Manual Of Determinative Bacteriology*. In: Bergey DH (Edt.), Lippincott Williams & Wilkins, USA.
22. Garrity GM, Bell JA, Lilburn T (2005) The Revised Road Map To The Manual. *JBSM* 2: 159-220.
23. Ray Butler W (2015) Segniliparaceae. *JBS MOSOA & Bacteria*, p. 1-1.
24. Goodfellow M, Trujillo M (2015) Brevibacteriaceae. *EJBS & Bacteria*, p. 1-1.
25. Normand P, Benson DR (2015a) Geodermatophilaceae. *JBS MOSOA & Bacteria*, p. 1-2.
26. Normand P, Benson DR (2015c) Sporichthyaceae. *JBS MOSOA & Bacteria*, p. 1-1.
27. Chen WF, Tao TS (2015) N Akamurellaceae, p. 1-2.
28. Kämpfer P, Glaeser SP (2015) C Rytosporangiaceae. *JBS MOSOA & Bacteria*, p. 1-4.
29. Normand P, Berry A, Benson DR (2015d) Acidothermaceae. *JBS MOSOA & Bacteria*, p. 1-1.
30. Normand P, Fernandez MP (2015e) F Rankiaceae. *JBS MOSOA & Bacteria*, p. 1-2.
31. Labeda DP (2015) Stackebrandtia. *JBS MOSOA & Bacteria*, p. 1-7.
32. Dong L, Salam N, Li W (2015) Haloglycomyces. *Microbial Systematics and Microbial Ecology*, p. 1-5.
33. Tang SK, Zhi XY, Li WJ (2015a) Jiangellaceae. *JBS MOSOA & Bacteria*, p. 1-1.
34. Normand P, Benson DR (2015b) Kineosporiaceae. *JBS MOSOA & Bacteria*, p. 1-2.
35. Evtushenko LI (2015) Microbacteriaceae. *JBS Bacteria*, p. 1-14.
36. Goodfellow M (2015) Tsukamurellaceae. *JBS MOSOA & Bacteria*, p. 1-1.
37. Groth I, Glaeser SP, Kämpfer P (2015) Beutenbergiaceae. *JBS MOSOA & Bacteria*, p. 1-4.
38. Kämpfer P (2015) Rarobacteraceae. *JBS MOSOA & Bacteria*, p. 1-1.
39. Ramos CP, Fernández Garayzábal JF (2015) Sanguibacteraceae. *JBS MOSOA & Bacteria*, p. 1-5.
40. Stackebrandt E, Rainey FA, Ward Rainey NL (1997) Proposal For A New Hierarchic Classification System, *Actinobacteria Classis Nov.* *Microbiology Society* 47(2): 479-491.
41. Tang SK, Zhi XY, Li WJ (2015b) Ruaniaceae. *JBS MOSOA & Bacteria*, p. 1-3.
42. Tsukamoto T, Takeuchi M, Shida O, Murata H, Shirata AJ (2001) Proposal Of *Mycetocola* Gen. Nov. In The Family Microbacteriaceae And Three New Species, *Mycetocola Saprophilus* Sp. Nov., *Mycetocola Tolaasinivorans* Sp. Nov. And *Mycetocola Lacteus* Sp. Nov., Isolated From Cultivated Mushroom, *Pleurotus Ostreatus*. *Int J Syst Evol Microbiol* 51(3): 937-944.
43. Evtushenko LI, Takeuchi M (2006) The Family Microbacteriaceae. *JTP* 3: 1020-1098.
44. Patrick S, McDowell A (2015) Propionibacteriaceae. *JBS MOSOA & Bacteria*, p. 1-2.
45. Evtushenko LI, Ariskina EV (2015) Nocardioidaceae, p. 1-18.
46. Teo WFA, Tan GYA, Li WJ (2021) Taxonomic Note On The Family Pseudonocardiaceae Based On Phylogenomic Analysis And Descriptions Of *Allosaccharopolyspora* Gen. Nov. And *Halosaccharopolyspora* Gen. Nov. *Int J Syst Evol Microbiol* 71(10): 005075.
47. Ay H, Saygin H, Sahin N (2020) Phylogenomic Revision Of The Family Streptosporangiaceae, Reclassification Of *Desertactinospora*

- Gelatinilytica As Spongiactinospora Gelatinilytica Comb. Nov. And A Taxonomic Home For The Genus Sinosporangium In The Family Streptosporangiaceae. *Int J Syst Evol Microbiol* 70(4): 2569-2579.
48. Harmsen HJ, Wildeboer Veloo AC, Grijpstra J, Knol J, Degener JE, et al. (2000) Development of 16s Rrna-Based Probes For The Coriobacterium Group And The Atopobium Cluster And Their Application For Enumeration Of Coriobacteriaceae In Human Feces From Volunteers Of Different Age Groups. *Appl Environ Microbiol* 66(10): 4523-4527.
49. Sorokin DY, Van Pelt S, Tourova TP, Evtushenko LI (2009) Nitriliruptor Alkaliphilus Gen. Nov., Sp. Nov., A Deep-Lineage Haloalkaliphilic Actinobacterium From Soda Lakes Capable Of Growth On Aliphatic Nitriles, And Proposal Of Nitriliruptoraceae Fam. Nov. And Nitriliruptorales Ord. Nov. *Int J Syst Evol Microbiol* 59: 248-253.
50. Suzuki KI (2015) Rubrobacteraceae. *JBS MOSOA & Bacteria*, p. 1-3.
51. Walsh T, Standiford H, Reboli A, John J, Mulligan M, et al. (1993) Randomized Double-Blinded Trial Of Rifampin With Either Novobiocin Or Trimethoprim-Sulfamethoxazole Against Methicillin-Resistant Staphylococcus Aureus Colonization: Prevention Of Antimicrobial Resistance And Effect Of Host Factors On Outcome. *Antimicrob Agents Chemother* 37(6): 1334-1342.
52. Rath JP, Kinast S, Maier ME (2005) Synthesis Of The Fully Functionalized Core Structure Of The Antibiotic Abyssomicin C. *Org Lett* 7(14): 3089-3092.
53. Riley MA (1998) Molecular Mechanisms Of Bacteriocin Evolution. *JAROG* 32: 255-278.
54. Uggowitz KA, Habibi Y, Wei W, Moitessier N, Thibodeaux C (2021) Mutations In Dynamic Structural Elements Alter The Kinetics And Fidelity Of The Multifunctional Class Ii Lanthipeptide Synthetase, Halm2. *Biochemistry* 60(5): 412-430.
55. Rea MC, Ross RP, Cotter PD, Hill C (2011) Classification Of Bacteriocins From Gram-Positive Bacteria. *Prokaryotic Antimicrobial Peptides*. Springer, p. 29-33.
56. Dischinger J, Chipalu SB, Bierbaum GJ (2014) Lantibiotics: Promising Candidates For Future Applications In Health Care. *Int J Med Microbiol* 304(1): 51-62.
57. Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, et al. (2008) Determining The Structure And Mode Of Action Of Microbisporicin, A Potent Lantibiotic Active Against Multiresistant Pathogens. *Chem Biol* 15(1): 22-31.
58. Pridmore D, Rekhif N, Pittet A, Suri B, Mollet B (1996) Variacin, A New Lanthionine-Containing Bacteriocin Produced By Micrococcus Varians: Comparison To Lactacin 481 Of Lactococcus Lactis. *JA & Microbiology E* 62(5): 1799-1802.
59. Seibert G, Vértesy L, Wink J, Winkler I, Süßmuth R, et al. (2008) Antibacterial And Antiviral Peptides From Actinomadura Namibiensis. Google Patents.
60. Carrano L, Abbondi M, Turconi P, Candiani G, Marinelli FJ (2015) A Novel Microbisporicin Producer Identified By Early Dereplication During Lantibiotic Screening 2015: 419383.
61. Cruz JOC, Iorio M, Monciardini P, Simone M, Brunati C, et al. (2015) Brominated Variant Of The Lantibiotic Nai-107 With Enhanced Antibacterial Potency. *J Nat Prod* 78(11): 2642-2647.
62. Münch D, Müller A, Schneider T, Kohl B, Wenzel M, et al. (2014) The Lantibiotic Nai-107 Binds To Bactoprenol-Bound Cell Wall Precursors And Impairs Membrane Functions. *J Biol Chem* 289(17): 12063-12076.
63. Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, et al. (2007) A Novel Lantibiotic Acting On Bacterial Cell Wall Synthesis Produced By The Uncommon Actinomycete Planomonospora Sp 46(20): 5884-5895.
64. Holtsmark I, Mantzilas D, Eijsink V, Brurberg M (2007) The Tomato Pathogen Clavibacter Michiganensis Ssp. Michiganensis: Producer Of Several Antimicrobial Substances. *J Appl Environ Microbiol* 72(9): 5814-5821.
65. Holtsmark I, Mantzilas D, Eijsink V, Brurberg M (2006) Purification, Characterization, And Gene Sequence Of Michiganin A, An Actagardine-Like Lantibiotic Produced By The Tomato Pathogen Clavibacter Michiganensis Subsp. Michiganensis 72(9): 5814-5821.
66. Brötz H, Bierbaum G, Reynolds PE, Sahl HG (1997) The Lantibiotic Mersacidin Inhibits Peptidoglycan Biosynthesis At The Level Of Transglycosylation. *Eur J Biochem* 246(1): 193-199.
67. Arioli V, Berti M, Silvestri LG (1976) Gardimycin, A New Antibiotic From Actinoplanes Iii. *Biological Properties* 29(5): 511-515.
68. Sahl HG, Bierbaum G (1998) Lantibiotics: Biosynthesis And Biological Activities Of Uniquely Modified Peptides From Gram-Positive Bacteria. 52: 41-79.
69. Naruse N, Tenmyo O, Tomita K, Konishi M, Miyaki T, et al. (1989) Lanthiopeptin, A New Peptide Antibiotic Production, Isolation And Properties Of Lanthiopeptin. *J Antibiot (Tokyo)* 42(6): 837-845.
70. Meindl K, Schmiederer T, Schneider K, Reicke A, Butz D, et al. (2010) Labyrinthopeptins: A New Class Of Carbacyclic Lantibiotics. *Angew Chem Int Ed Engl* 49(6): 1151-1154.
71. Féris G, Petrova MI, Andrei G, Huskens D, Hoorelbeke B, et al. (2013) The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-Hiv And Anti-Hsv Activity With Potential For Microbicidal Applications *PLoS ONE* 8(5): E64010.
72. Iorio M, Sasso O, Maffioli SI, Bertorelli R, Monciardini P, et al. (2014) A Glycosylated, Labionin-Containing Lanthipeptide With Marked Antinociceptive Activity. *ACS Chem Biol* 9(2): 398-404.
73. Tiwari K, Gupta RK (2012) Rare Actinomycetes: A Potential Storehouse For Novel Antibiotics. *Critical Reviews In Biotechnology* 32(2): 108-132.
74. Hug JJ, Bader CD, Remškar M, Cirnski K, Müller R (2018) Concepts And Methods To Access Novel Antibiotics From Actinomycetes. *Antibiotics* 7(2): 44.
75. Takahashi Y, Nakashima T (2018) Actinomycetes, An Inexhaustible Source Of Naturally Occurring Antibiotics. *Antibiotics* 7(2): 45.
76. Mahajan GB, Balachandran L (2012) Antibacterial Agents From Actinomycetes-A Review. *Front Biosci (Elite Ed)* 4: 240-53.
77. Peng Y, Cao XY, Tian W, Sun Y, Wu CF, et al. (2008) Screening And Identification Of An Anti-Tumor Soil Actinomycetes Strain. *Journal Of Shenyang Pharmaceutical University* 7: 1334.
78. Qasim B, Risan MH (2017) Anti-Tumor And Antimicrobial Activity Of Antibiotic Produced By Streptomyces Spp. *World Journal Of Pharmaceutical Research* 6(4): 116-128.
79. Ahmed M, Ahmed R, Merdash A, El Kabbany H (2013) Isolation And Description Of Antimicrobial And Anti-Tumor Produced By Actinomycetes Sp. Al-Azhar *Bulletin Of Science* 24(2): 49-64.
80. Guimarães TC, Gomes TS, Fernandes CD, Barros FD, Oliveira KV, et al. (2020) Antitumor Microbial Products By Actinomycetes Isolated. *Microbial Technology For Health And Environment* 22: 113.
81. Lashgari NA, Roudsari NM, Momtaz S, Ghanaatian N, Kohansal P, et al. (2020) Targeting Mammalian Target Of Rapamycin: Prospects For The Treatment Of Inflammatory Bowel Diseases. *Current Medicinal Chemistry* 28(8): 1605-1624.
82. Lashgari NA, Roudsari NM, Zandi N, Pazoki B, Rezaei A, et al. (2021a) Current Overview Of Opioids In Progression Of Inflammatory Bowel Disease; Pharmacological And Clinical Considerations. *Molecular Biology Reports* 48(1): 855-874.

83. Roudsari NM, Lashgari NA, Momtaz S, Roufogalis B, Abdolghaffari AH, et al. (2021) Ginger: A Complementary Approach For Management Of Cardiovascular Diseases. *Biofactors* 47(6): 933-951.
84. Lashgari NA, Momeni Roudsari N, Khayatan D, Shayan M, Momtaz S, et al. (2021b) Ginger And Its Constituents: Role In Treatment Of Inflammatory Bowel Disease. *Biofactors* 48: 7-21.
85. Park NH, Hong YK, Cho JY (2006) Screening Anti-Inflammatory Actinomycetes Isolated From Seaweeds And Marine Sediments. *Korean Journal Of Fisheries And Aquatic Sciences* 39(4): 333-337.
86. Singh R, Dubey A (2015) Endophytic Actinomycetes As Emerging Source For Therapeutic Compounds. *Indo Global J Pharm Sci* 5(2): 106-116.
87. Dahari DE, Salleh RM, Mahmud F, Chin LP, Embi N, et al. (2016) Anti-Malarial Activities Of Two Soil Actinomycete Isolates From Sabah Via Inhibition Of Glycogen Synthase Kinase β . *Tropical Life Sciences Research* 27(2): 53.
88. Hamed J, Mohammadipanah F, Ventosa A (2013) Systematic And Biotechnological Aspects Of Halophilic And Halotolerant Actinomycetes. *Extremophiles* 17(1): 1-13.
89. Sumathi R, Ruby S, Duraisamy K, Sivakumar T (2010) Extraction Of Actinomycetes From Soil Sediments By Submerged Fermentation: Purification, Characterization And Its Anti-Viral Activity. *Research Journal Of Pharmacy And Technology* 3(3): 843-846.
90. Ramya S, Shanmugasundaram T, Balagurunathan R (2015) Biomedical Potential Of Actinobacterially Synthesized Selenium Nanoparticles With Special Reference To Anti-Biofilm, Anti-Oxidant, Wound Healing, Cytotoxic And Anti-Viral Activities. *Journal Of Trace Elements In Medicine And Biology* 32: 30-39.
91. Janardhan A, Kumar AP, Viswanath B, Saigopal D, Narasimha G (2014) Production Of Bioactive Compounds By Actinomycetes And Their Antioxidant Properties. *Biotechnology Research International*: 217030.
92. Savi D, Haminiuk C, Sora G, Adamoski D, Kenski J, et al. (2015) Antitumor, Antioxidant And Antibacterial Activities Of Secondary Metabolites Extracted By Endophytic Actinomycetes Isolated From *Vochysia Divergens*. *International Journal Of Pharmaceutical, Chemical & Biological Sciences* 5(1): 347-356.
93. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, et al. (2012a) Hidden Killers: Human Fungal Infections. *Science Translational Medicine* 4(165): 165.
94. Kim JY (2016) Human Fungal Pathogens: Why Should We Learn? *J Microbiol* 54(3): 145-148.
95. Rodrigues ML, Nosanchuk JD (2020) Fungal Diseases As Neglected Pathogens: A Wake-Up Call To Public Health Officials. *Plos Neglected Tropical Diseases* 14: E0007964.
96. Casadevall A (2018) Fungal Diseases In The 21st Century: The Near And Far Horizons. *Pathogens & Immunity* 3(2): 183-196.
97. Brown GD, Denning DW, Levitz SM (2012b) Tackling Human Fungal Infections. *American Association for the Advancement of Science* 336(6082): 647.
98. Carvalho A, Cunha C, Pasqualotto AC, Pitzurra L, Denning DW, et al. (2010) Genetic Variability Of Innate Immunity Impacts Human Susceptibility To Fungal Diseases. *International Journal Of Infectious Diseases* 14(6): E460-E468.
99. Templeton SP, Rivera A, Hube B, Jacobsen ID (2018) Immunity To Human Fungal Pathogens: Mechanisms Of Host Recognition, Protection, Pathology, And Fungal Interference. *Frontiers In Immunology*: 2337.
100. Märtson AG, Alfenaar JWC, Brüggemann RJ, Hope W (2022) Precision Therapy For Invasive Fungal Diseases. *Journal Of Fungi* 8(1): 18.
101. Lamari L, Zitouni A, Boudjella H, Badji B, Sabaou N, et al. (2002) New Dithiopyrrolone Antibiotics From *Saccharothrix* Sp. Sa 233 I. Taxonomy, Fermentation, Isolation And Biological Activities. *J Antibiot (Tokyo)* 55(8): 696-701.
102. Merrouche R, Bouras N, Coppel Y, Mathieu F, Monje MC, et al. (2010) Dithiopyrrolone Antibiotic Formation Induced By Adding Valeric Acid To The Culture Broth Of *Saccharothrix Algeriensis*. *J Nat Prod* 73(6): 1164-1166.
103. Merrouche R, Bouras N, Coppel Y, Mathieu F, Sabaou N, et al. (2011) New Dithiopyrrolone Antibiotics Induced By Adding Sorbic Acid To The Culture Medium Of *Saccharothrix Algeriensis* Nrrl B-24137. *FEMS Microbiol Lett* 318(1): 41-46.
104. Merrouche R, Yekkour A, Coppel Y, Bouras N, Lamari L, et al. (2019) Effective Biosynthesis Of Benzoyl-Pyrrothine Dithiopyrrolone Antibiotic By Cinnamic Acid-Precursor Addition In Culture Of *Saccharothrix Algeriensis* Nrrl B-24137. *Lett Appl Microbiol* 68: 165-172.
105. Zitouni A, Boudjella H, Mathieu F, Sabaou N, Lebrihi A (2004) Mutactimycin Pr, A New Anthracycline Antibiotic From *Saccharothrix* Sp. Sa 103 I. Taxonomy, Fermentation, Isolation And Biological Activities. *Antibiot (Tokyo)* 57(6): 367-372.
106. Boudjella H, Zitouni A, Coppel Y, Mathieu F, Monje MC, et al. (2010) Antibiotic R2, A New Angucyclinone Compound From *Streptosporangium* Sp. Sg3. 63(12): 709-711.
107. Badji B, Mostefaoui A, Sabaou N, Lebrihi A, Mathieu F, et al. (2007) Isolation And Partial Characterization Of Antimicrobial Compounds From A New Strain *Nonomuraea* Sp94 34(6): 403-412.
108. Aouiche A, Sabaou N, Meklat A, Zitouni A, Bijani C, et al. (2012) *Saccharothrix* Sp. Pal54, A New Chloramphenicol-Producing Strain Isolated From A Saharan Soil. *World Journal of Microbiology and Biotechnology* 28(3): 943-951.
109. Djinni I, Defant A, Kecha M, Mancini I (2014) Metabolite Profile Of Marine-Derived Endophytic *S Treptomyces Sundarbansensis* Wr 1 L 1 S 8 By Liquid Chromatography-Mass Spectrometry And Evaluation Of Culture Conditions On Antibacterial Activity And Mycelial Growth. *J Appl Microbiol* 116(1): 39-50.
110. Boubetra D, Sabaou N, Zitouni A, Bijani C, Lebrihi A, et al. (2013) Taxonomy And Chemical Characterization Of New Antibiotics Produced By *Saccharothrix* Sa198 Isolated From A Saharan Soil 168(4): 223-230.
111. Aouiche A, Meklat A, Bijani C, Zitouni A, Sabaou N, et al. (2015) Production Of Vineomycin A1 And Chaetoglobosin A By *Streptomyces* Sp. Pal114 65: 1351-1359.
112. Yekkour A, Meklat A, Bijani C, Toumatia O, Errakhi R, et al. (2015) A Novel Hydroxamic Acid-Containing Antibiotic Produced By A Saharan Soil-Living *Streptomyces* Strain. *Lett Appl Microbiol* 60(6): 589-596.
113. Driche EH, Belghit S, Bijani C, Zitouni A, Sabaou N, et al. (2015) A New *Streptomyces* Strain Isolated From Saharan Soil Produces Di-(2-Ethylhexyl) Phthalate, A Metabolite Active Against Methicillin-Resistant *Staphylococcus Aureus* 65(3): 1341-1350.
114. Lahoum A, Sabaou N, Bijani C, Bouras N, Pont F, et al. (2019) Antimicrobial Activities Of Novel Bipyridine Compounds Produced By A New Strain Of *Saccharothrix* Isolated From Saharan Soil. *Saudi Pharm J* 27(1): 56-65.
115. Taechowisan T, Peberdy JF, Lumyong S (2003) Isolation Of Endophytic Actinomycetes From Selected Plants And Their Antifungal Activity. *World Journal Of Microbiology And Biotechnology* 19(4): 381-385.
116. Sharma H, Parihar L (2010) Antifungal Activity Of Extracts Obtained From Actinomycetes. *Journal Of Yeast And Fungal Research* 1(10): 197-200.

117. Inderiati S, Franco CM (2008) Isolation And Identification Of Endophytic Actinomycetes And Their Antifungal Activity. *J Biotechnol Res Trop Reg* 1: 1-6.
118. Arasu MV, Esmail GA, AlDhabi NA, Ponmurugan K (2016) Managing Pests And Diseases Of Grain Legumes With Secondary Metabolites From Actinomycetes. *Plant Growth Promoting Actinobacteria*. Springer, p. 83-98.
119. K Sharma, A Beniwal, V Kumar, R Thakur K, Sharma R (2015) Secondary Metabolites Derived From Actinomycetes: Iron Modulation And Their Therapeutic Potential. *The Natural Products Journal* 5(2): 72-81.
120. Tekaya SB, Tipayno S, Chandrasekaran M, Yim WJ, Sa TM (2012) Actinobacteria Isolation From Metal Contaminated Soils For Assessment Of Their Metal Resistance And Plant Growth Promoting (Pgp) Characteristics. *Korean Journal Of Soil Science And Fertilizer* 45(4): 593-601.
121. Luong HT, Vu TN, Ha TT, Nguyen KBT, Van Dao TH (2018) Effects Of Some Microelements On Antifungal Activity And Biomass Of The Actinomycetes Producing Validamycin-A. *Journal Of Vietnamese Environment* 9(3): 128-131.
122. Lewin GR, Carlos C, Chevrette MG, Horn HA, McDonald BR, et al. (2016) Evolution And Ecology Of Actinobacteria And Their Bioenergy Applications. *Annual Review Of Microbiology* 70: 235-254.
123. Anandan R, Dharumadurai D, Manogaran GP (2016) An Introduction To Actinobacteria. In: Anandan R, Dharumadurai D, Manogaran GP (Eds.), *Intechopen*.
124. Hui MLY, Tan LTH, Letchumanan V, He YW, Fang CM, et al. (2021) The Extremophilic Actinobacteria: From Microbes To Medicine. *Antibiotics* 10(6): 682.
125. Benndorf R, Guo H, Sommerwerk E, Weigel C, Garcia Altares M, et al. (2018) Natural Products From Actinobacteria Associated With Fungus-Growing Termites. *Antibiotics* 7(3): 83.
126. Anasane N, Golińska P, Wypij M, Rathod D, Dahm H, et al. (2016) Acidophilic Actinobacteria Synthesised Silver Nanoparticles Showed Remarkable Activity Against Fungi-Causing Superficial Mycoses In Humans. *Mycoses* 59(3): 157-166.
127. Bundale S, Singh J, Begde D, Nashikkar N, Upadhyay A (2019) Rare Actinobacteria: A Potential Source Of Bioactive Polyketides And Peptides. *World Journal Of Microbiology And Biotechnology* 35(6): 92.
128. Cao P, Li C, Wang H, Yu Z, Xu X, et al. (2020) Community Structures And Antifungal Activity Of Root-Associated Endophytic Actinobacteria In Healthy And Diseased Cucumber Plants And *Streptomyces* Sp. Haag3-15 As A Promising Biocontrol Agent. *Microorganisms* 8(2): 236.
129. Das R, Romi W, Das R, Sharma HK, Thakur D (2018) Antimicrobial Potentiality Of Actinobacteria Isolated From Two Microbiologically Unexplored Forest Ecosystems Of Northeast India. *Bmc Microbiology* 18(1): 77.
130. Fang X, Shen J, Wang J, Chen ZL, Chen ZY, et al. (2018) Antifungal Activity Of 3-Acetylbenzamide Produced By Actinomycete Wa23-4-4 From The Intestinal Tract Of *Periplaneta Americana*. *Journal Of Microbiology* 56: 516-523.
131. Hemala L, Zhang D, Margesin R (2014) Cold-Active Antibacterial And Antifungal Activities And Antibiotic Resistance of Bacteria Isolated From An Alpine Hydrocarbon-Contaminated Industrial Site. *Research In Microbiology* 165(6): 447-456.
132. Kämpfer P (2006) The Family Streptomycetaceae, Part I: Taxonomy. *JTP* 3: 538-604.
133. Labeda D, Testa R, Lechevalier M, Lechevalier H (1985) Glycomyces, A New Genus Of The Actinomycetales. *JJOS & Microbiology* 35: 417-421.
134. Lekhak B, Singh A, Bhatta DR (2018) Antibacterial And Antifungal Property Of Actinomycetes Isolates From Soil And Water Of Nepal. *Journal Of Nepal Health Research Council* 16(2): 136-139.
135. Liu C, Chen X, Liu T, Lian B, Gu Y, et al. (2007) Study Of The Antifungal Activity Of *Acinetobacter Baumannii* Lch001 In Vitro And Identification Of Its Antifungal Components. *Applied Microbiology And Biotechnology* 76(2): 459-466.
136. Liu C, Zhuang X, Yu Z, Wang Z, Wang Y, et al. (2019) Community Structures And Antifungal Activity Of Root-Associated Endophytic Actinobacteria Of Healthy And Diseased Soybean. *Microorganisms* 7(8): 243.
137. Mendes TD, Borges WS, Rodrigues A, Solomon SE, Vieira PC, et al. (2013) Anti-Candida Properties Of Urauchimycins From Actinobacteria Associated With *Trachymyrmex* Ants. *Biomed Research International*: 835081.
138. Nafis A, Elhidar N, Oubaha B, Samri SE, Niedermeyer T, et al. (2018) Screening For Non-Polyenic Antifungal Produced By Actinobacteria From Moroccan Habitats: Assessment Of Antimycin A19 Production By *Streptomyces Albidoflavus* As25. *International Journal Of Molecular And Cellular Medicine* 7(2): 133-145.
139. Pavan Kumar J, Gomathi A, Vasconcelos V, Gothandam K (2018) Bioactivity Assessment Of Indian Origin-Mangrove Actinobacteria Against *Candida Albicans*. *Marine Drugs* 16(2): 60.
140. Stackebrandt E (2015) *Dermatophilaceae*. *JBS MOSOA & Bacteria*, p. 1-3.
141. Wang Z, Yu Z, Zhao J, Zhuang X, Cao P, et al. (2020) Community Composition, Antifungal Activity And Chemical Analyses Of Ant-Derived Actinobacteria. *Frontiers In Microbiology*, pp. 201.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2022.45.007205

Naser-Aldin Lashgari. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>